Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5219752
Max Phase: Preclinical
Molecular Formula: C71H109IN22O20S4
Molecular Weight: 1845.96
Associated Items:
ID: ALA5219752
Max Phase: Preclinical
Molecular Formula: C71H109IN22O20S4
Molecular Weight: 1845.96
Associated Items:
Canonical SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H]2NC(=O)[C@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)c(I)c1)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@H](CC(=O)N[C@@H](CCCCN)C(=O)O)Cc1ccc(O)cc1)CSSC2(C)C
Standard InChI: InChI=1S/C71H109IN22O20S4/c1-35(95)55-65(110)89-46(30-54(100)101)67(112)94-25-9-14-50(94)64(109)87-43(13-8-24-81-70(78)79)59(104)90-48-33-116-115-32-47(84-53(99)31-75)63(108)93-56(66(111)92-55)71(2,3)118-117-34-49(61(106)82-38(26-36-15-18-39(96)19-16-36)29-52(98)83-44(68(113)114)10-4-5-21-73)91-58(103)41(11-6-22-74)85-60(105)45(28-37-17-20-51(97)40(72)27-37)88-57(102)42(86-62(48)107)12-7-23-80-69(76)77/h15-20,27,35,38,41-50,55-56,95-97H,4-14,21-26,28-34,73-75H2,1-3H3,(H,82,106)(H,83,98)(H,84,99)(H,85,105)(H,86,107)(H,87,109)(H,88,102)(H,89,110)(H,90,104)(H,91,103)(H,92,111)(H,93,108)(H,100,101)(H,113,114)(H4,76,77,80)(H4,78,79,81)/t35-,38+,41+,42+,43+,44+,45+,46+,47-,48+,49+,50+,55+,56-/m1/s1
Standard InChI Key: UDWUBMUQFIDTJI-WTXMZRODSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1845.96 | Molecular Weight (Monoisotopic): 1844.6116 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM.. (2021) Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism., 64 (13.0): [PMID:34142837] [10.1021/acs.jmedchem.1c00512] |
Source(1):